Additionally, there is a risk that in the high population cohort of men with suspected or diagnosed prostate cancer who require PSMA imaging, many may have significantly delayed PSMA imaging with PET technology due to insufficient PET facilities, and the inability to perform the scan quickly also creates potential problems in further diagnostic and therapeutic optimal approach. The gene discussed is FOLH1; the disease is prostate cancer.